| 14-HDHA | 14-hydroxy-docosahexaenoic Acid |
| 17-HDHA | 17-hydroxy-docosahexaenoic Acid |
| 18-HEPE | 18-hydroxy-eicosapentaenoic Acid |
| AE | Adverse Event |
| AEMPS | Agencia Española de Medicamentos y Productos Sanitarios |
| AFC | Alveolar Fluid Clearance |
| AR | Adverse Reaction |
| ARDS | Acute Respiratory Distress Syndrome |
| CRF | Case Report Form |
| CRO | Clinical Research Organisation |
| CSR | Clinical Study Report |
| DHA | Docosahexaenoic Acid |
| EC | Ethics Committee |
| EoS | End of Study |
| EPA | Eicosapentaenoic Acid |
| FTH | Fundación Teófilo Hernando |
| FSS | Fatigue Severity Scale |
| GCP | Good Clinical Practice |
| IC | Informed Consent |
| IP | Investigational Product |
| ISF | Investigator Site File |
| ITT | Intention To Treat |
| LTB4 | Leucotrien B4 |
| LX (A4, B4) | Lipoxins |
| Ma (R1, R2) | Maresins |
| MedDRA | Medical Dictionary for Regulatory Activities |
| mMRC | Modified Medical Research Council |
| PD (1, X) | Protectins |
| PG (E2, D2, F2α) | Prostaglandins |
| PI | Principal Investigator |
| PP | Per Protocol |
| SAE | Severe Adverse Event |
| SEMG | Sociedad Española de Médicos Generales y de Familia (Spanish society of general practitioners and family doctors) |
| SPM | Specialized Pro-resolving Mediator |
| SOP | Standard Operation Procedure |
| SS | Safety Set |
| TXB2 | Thromboxane B2 |